169 related articles for article (PubMed ID: 31908357)
1. Two unique HLA-A*0201 restricted peptides derived from cyclin E as immunotherapeutic targets in leukemia.
He H; Kondo Y; Ishiyama K; Alatrash G; Lu S; Cox K; Qiao N; Clise-Dwyer K; St John L; Sukhumalchandra P; Ma Q; Molldrem JJ
Leukemia; 2020 Jun; 34(6):1626-1636. PubMed ID: 31908357
[TBL] [Abstract][Full Text] [Related]
2. Identification of a novel HLA-A2-restricted cytotoxic T lymphocyte epitope from cancer-testis antigen PLAC1 in breast cancer.
Liu W; Zhai M; Wu Z; Qi Y; Wu Y; Dai C; Sun M; Li L; Gao Y
Amino Acids; 2012 Jun; 42(6):2257-65. PubMed ID: 21710262
[TBL] [Abstract][Full Text] [Related]
3. Identification of HLA-A*0201-restricted CTL Epitopes for MLAA-34-specific Immunotherapy for Acute Monocytic Leukemia.
Bai J; Wang J; Yang Y; Wang F; He A; Zhang W
J Immunother; 2021 May; 44(4):141-150. PubMed ID: 33596023
[TBL] [Abstract][Full Text] [Related]
4. Identification of cyclophilin B-derived peptides capable of inducing histocompatibility leukocyte antigen-A2-restricted and tumor-specific cytotoxic T lymphocytes.
Tamura M; Nishizaka S; Maeda Y; Ito M; Harashima N; Harada M; Shichijo S; Itoh K
Jpn J Cancer Res; 2001 Jul; 92(7):762-7. PubMed ID: 11473727
[TBL] [Abstract][Full Text] [Related]
5. A novel HLA-A*0201 restricted peptide derived from cathepsin G is an effective immunotherapeutic target in acute myeloid leukemia.
Zhang M; Sukhumalchandra P; Enyenihi AA; St John LS; Hunsucker SA; Mittendorf EA; Sergeeva A; Ruisaard K; Al-Atrache Z; Ropp PA; Jakher H; Rodriguez-Cruz T; Lizee G; Clise-Dwyer K; Lu S; Molldrem JJ; Glish GL; Armistead PM; Alatrash G
Clin Cancer Res; 2013 Jan; 19(1):247-57. PubMed ID: 23147993
[TBL] [Abstract][Full Text] [Related]
6. High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells.
Quintarelli C; Dotti G; Hasan ST; De Angelis B; Hoyos V; Errichiello S; Mims M; Luciano L; Shafer J; Leen AM; Heslop HE; Rooney CM; Pane F; Brenner MK; Savoldo B
Blood; 2011 Mar; 117(12):3353-62. PubMed ID: 21278353
[TBL] [Abstract][Full Text] [Related]
7. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells.
Schmidt SM; Schag K; Müller MR; Weck MM; Appel S; Kanz L; Grünebach F; Brossart P
Blood; 2003 Jul; 102(2):571-6. PubMed ID: 12576330
[TBL] [Abstract][Full Text] [Related]
8. Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide.
Voutsas IF; Anastasopoulou EA; Tzonis P; Papamichail M; Perez SA; Baxevanis CN
J Immunother Cancer; 2016; 4():75. PubMed ID: 27891225
[TBL] [Abstract][Full Text] [Related]
9. Prediction and identification of HLA-A*0201-restricted epitopes from leukemia-associated protein MLAA-22 which elicit cytotoxic T lymphocytes.
Li J; Bai J; Gu L; He A; Wang J; Wang J; Zhang P; Zhang W
Med Oncol; 2014 Dec; 31(12):293. PubMed ID: 25355639
[TBL] [Abstract][Full Text] [Related]
10. HLA-A2-restricted cytotoxic T lymphocyte epitopes from human heparanase as novel targets for broad-spectrum tumor immunotherapy.
Chen T; Tang XD; Wan Y; Chen L; Yu ST; Xiong Z; Fang DC; Liang GP; Yang SM
Neoplasia; 2008 Sep; 10(9):977-86. PubMed ID: 18714399
[TBL] [Abstract][Full Text] [Related]
11. Two proliferation-related proteins, TYMS and PGK1, could be new cytotoxic T lymphocyte-directed tumor-associated antigens of HLA-A2+ colon cancer.
Shichijo S; Azuma K; Komatsu N; Ito M; Maeda Y; Ishihara Y; Itoh K
Clin Cancer Res; 2004 Sep; 10(17):5828-36. PubMed ID: 15355913
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cell-based vaccines in patients with hematological malignancies.
Brugger W; Schneider A; Schammann T; Dill P; Grünebach F; Bühring HJ; Kanz L; Brossart P
Ann N Y Acad Sci; 2001 Jun; 938():359-62; discussion 362-3. PubMed ID: 11458523
[TBL] [Abstract][Full Text] [Related]
13. Identification of HLA-A*0201-presented T cell epitopes derived from the oncofetal antigen-immature laminin receptor protein in patients with hematological malignancies.
Siegel S; Wagner A; Friedrichs B; Wendeler A; Wendel L; Kabelitz D; Steinmann J; Barsoum A; Coggin J; Rohrer J; Dreger P; Schmitz N; Zeis M
J Immunol; 2006 Jun; 176(11):6935-44. PubMed ID: 16709854
[TBL] [Abstract][Full Text] [Related]
14. Identification of a novel peptide derived from the M-phase phosphoprotein 11 (MPP11) leukemic antigen recognized by human CD8+ cytotoxic T lymphocytes.
Al Qudaihi G; Lehe C; Dickinson A; Eltayeb K; Rasheed W; Chaudhri N; Aljurf M; Dermime S
Hematol Oncol Stem Cell Ther; 2010; 3(1):24-33. PubMed ID: 20231810
[TBL] [Abstract][Full Text] [Related]
15. Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells.
Smith HA; McNeel DG
J Immunother; 2011 Oct; 34(8):569-80. PubMed ID: 21904219
[TBL] [Abstract][Full Text] [Related]
16. [Identification of a novel HLA-A2-restrictive CTL epitope of an ovary cancer-associated antigen OVA66].
Jin S; Wang Y; Wang SJ; Zhang HZ; Li MX; Chen Y; Ge HL
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 Mar; 21(2):233-6, 242. PubMed ID: 15766414
[TBL] [Abstract][Full Text] [Related]
17. HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL.
Harao M; Hirata S; Irie A; Senju S; Nakatsura T; Komori H; Ikuta Y; Yokomine K; Imai K; Inoue M; Harada K; Mori T; Tsunoda T; Nakatsuru S; Daigo Y; Nomori H; Nakamura Y; Baba H; Nishimura Y
Int J Cancer; 2008 Dec; 123(11):2616-25. PubMed ID: 18770861
[TBL] [Abstract][Full Text] [Related]
18. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice.
Motomura Y; Ikuta Y; Kuronuma T; Komori H; Ito M; Tsuchihara M; Tsunoda Y; Shirakawa H; Baba H; Nishimura Y; Kinoshita T; Nakatsura T
Int J Oncol; 2008 May; 32(5):985-90. PubMed ID: 18425324
[TBL] [Abstract][Full Text] [Related]
19. Identification and characterization of HLA-class-I-restricted T-cell epitopes in the putative tumor-associated antigens P21-activated serin kinase 2 (PAK2) and cyclin-dependent kinase inhibitor 1A (CDKN1A).
Li G; Hundemer M; Wolfrum S; Ho AD; Goldschmidt H; Witzens-Harig M
Ann Hematol; 2006 Sep; 85(9):583-90. PubMed ID: 16718496
[TBL] [Abstract][Full Text] [Related]
20. Identification of novel human leukocyte antigen-A*0201-restricted, cytotoxic T lymphocyte epitopes on CD133 for cancer stem cell immunotherapy.
Ji J; Judkowski VA; Liu G; Wang H; Bunying A; Li Z; Xu M; Bender J; Pinilla C; Yu JS
Stem Cells Transl Med; 2014 Mar; 3(3):356-64. PubMed ID: 24375541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
